Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed through a tissue or cell sample to have locally advanced or metastatic pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer).
• People who have not yet received any systemic (whole-body) anti-cancer treatment for their cancer that has spread or returned.
• People who previously received chemotherapy, radiation, or immunotherapy before their cancer spread may be considered, as long as that treatment finished at least 6 months ago and the cancer did not return during that time.
• People who have at least one area of cancer that can be measured on a scan, according to standard measurement guidelines.
• People who meet specific medical criteria for either cachexia (significant unintended weight loss and/or reduced appetite and/or signs of inflammation) or pre-cachexia (early-stage weight-related decline with inflammation and reduced appetite), as defined by a recognised medical framework called the Fearon criteria (confirm with trial site for exact measurements).
• People aged 18 to 75, of any sex.
• People who are well enough to carry out light activity and self-care, rated 0 to 2 on a standard medical scale (ECOG performance status).
• People with an expected survival of more than 4 months.
• People whose blood cell counts, liver, kidney, heart, and clotting functions meet the required levels as measured by blood tests (confirm with trial site for exact values).
• Women who could become pregnant must have a negative pregnancy test within 3 days before starting the trial.
• Women who could become pregnant and are sexually active with male partners who have not had a vasectomy must use an accepted form of contraception from the start of the trial through to 120 days after the last dose.
• Male participants who are sexually active with women who could become pregnant must use effective contraception from the start of the trial through to 120 days after the last dose.

Who may not be able to join:

• People with active or untreated cancer that has spread to the brain or the lining of the brain and spinal cord, unless that spread has been previously treated, has been stable for at least 2 months, and high-dose steroid treatment has been stopped for more than 4 weeks.
• People with cancer-related pain that is not well controlled.
• People who have had blood clot-related conditions, a build-up of fluid in the abdomen, or swelling in the legs within the past 6 months.
• People who have had a different type of cancer within the past 5 years, unless it was a type considered very unlikely to spread or cause death and was treated successfully (for example, certain skin cancers, early-stage cervical changes, or localised prostate cancer treated with surgery).
• People who still have unresolved side effects from previous cancer treatments, other than hair loss.
• People whose cancer has spread to the lining of the abdomen (peritoneal metastases).
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
• People with hepatitis B who have detectable levels of the hepatitis B virus in their blood.
• People with hepatitis C who have detectable hepatitis C virus in their blood.
• People who test positive for HIV.
• People who have had major surgery (not including diagnostic procedures) within 28 days before joining, or who are expected to need major surgery during the study.
• People with significant heart conditions, such as a heart attack within the past 3 months, unstable heart rhythm, unstable chest pain, or a recent stroke or mini-stroke.
• People who have had a severe infection requiring hospitalisation within 4 weeks before starting, or an active infection requiring treatment within 2 weeks before starting (not including hepatitis B or C antiviral therapy).
• People who have difficulty swallowing, absorbing food, or who have uncontrolled vomiting, who cannot eat normally, or who require tube feeding or intravenous nutrition.
• People currently using or planning to use other medications that stimulate appetite or weight gain, such as certain steroids, progestins, thalidomide, olanzapine, or anamorelin (confirm with trial site for the full list).
• People with Cushing's syndrome, adrenal or pituitary gland problems, poorly controlled diabetes, or blood pressure that remains too high despite treatment.
• People who have had serious stomach or bowel problems within the past 6 months, including bleeding, obstruction, perforation, fistula, or abscess.
• People with a known allergy or sensitivity to any ingredient in the study drug.
• People whom the trial doctors consider unsuitable for any other medical reason.

Important: Always verify eligibility with the trial site directly before applying.